Docking protein 2 (DOK2)

Docking protein 2 (DOK2) is an enzymatically inert adaptor or scaffolding protein that serves as a docking platform for the assembly of multimolecular signaling complexes, especially downstream of tyrosine kinase signaling pathways[2][4][7]. It is constitutively phosphorylated in hematopoietic progenitors from patients with chronic myelogenous leukemia, where it is a critical substrate for the BCR-ABL oncoprotein[1][2]. DOK2 modulates signals from various cytokine receptors (e.g., influences IL-4, IL-2, and IL-3 responses), attenuates MAP kinase pathway activation, and plays a regulatory role in proliferation, differentiation, and immune cell function[2][4][7]. Loss or dysregulation of DOK2 function has been implicated in cancers such as CML and in abnormalities of immune system signaling[2][6].

Other names

p56dok-2Dok-2Downstream of tyrosine kinase 2p56(dok-2)p56DOKdocking protein 2, 56kDdocking protein 2, 56kDa

Drugs targeting this molecule would likely inhibit or modulate scaffolding/adaptor interactions to suppress aberrant signaling, especially in cancers where BCR-ABL signaling is involved[1][2][7].